EGFR and neoplasm: In our present work, we find that, beyond its EGFR tyrokinase inhibitory effect, gefitinib also has immunomodulatory effect in gefitinib-resistance cell lines, which can enhance immune recognization of tumor cells by NK cells and attenuate the inhibitory effect of tumor cells on NK cells.